Evercore ISI Reiterates Buy Rating for Gilead Sciences (GILD)

Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating restated by equities researchers at Evercore ISI in a research report issued on Friday, TipRanks reports.

Other analysts have also issued research reports about the stock. Wells Fargo & Co lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $95.00 to $68.00 in a research note on Monday, February 11th. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, April 9th. UBS Group upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $75.00 to $77.00 in a research note on Wednesday, April 10th. BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Monday, May 6th. Nine equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $81.61.

Shares of NASDAQ:GILD traded up $0.58 during midday trading on Friday, reaching $66.36. The company had a trading volume of 5,922,988 shares, compared to its average volume of 7,334,711. The company has a current ratio of 3.62, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09. The firm has a market cap of $83.25 billion, a PE ratio of 10.79, a price-to-earnings-growth ratio of 0.79 and a beta of 1.14. Gilead Sciences has a one year low of $60.32 and a one year high of $79.61.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.53 by $0.23. The business had revenue of $5.28 billion during the quarter, compared to analyst estimates of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The business’s revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.48 earnings per share. As a group, equities research analysts forecast that Gilead Sciences will post 6.6 EPS for the current fiscal year.

In other Gilead Sciences news, Director John Francis Cogan sold 2,868 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $64.89, for a total transaction of $186,104.52. Following the completion of the sale, the director now owns 57,728 shares in the company, valued at $3,745,969.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Richard James Whitley sold 9,534 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $65.48, for a total transaction of $624,286.32. Following the sale, the director now owns 34,669 shares of the company’s stock, valued at approximately $2,270,126.12. The disclosure for this sale can be found here. In the last quarter, insiders have sold 47,670 shares of company stock valued at $3,142,526. 0.20% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp boosted its holdings in shares of Gilead Sciences by 95.7% during the fourth quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 554,083 shares of the biopharmaceutical company’s stock valued at $34,658,000 after acquiring an additional 271,000 shares during the period. Chilton Capital Management LLC boosted its holdings in shares of Gilead Sciences by 3.5% during the fourth quarter. Chilton Capital Management LLC now owns 16,468 shares of the biopharmaceutical company’s stock valued at $1,030,000 after acquiring an additional 555 shares during the period. Nicholas Company Inc. boosted its holdings in shares of Gilead Sciences by 2.7% during the fourth quarter. Nicholas Company Inc. now owns 506,760 shares of the biopharmaceutical company’s stock valued at $31,697,000 after acquiring an additional 13,500 shares during the period. Sectoral Asset Management Inc boosted its holdings in shares of Gilead Sciences by 59.6% during the fourth quarter. Sectoral Asset Management Inc now owns 424,890 shares of the biopharmaceutical company’s stock valued at $26,577,000 after acquiring an additional 158,750 shares during the period. Finally, AIMZ Investment Advisors LLC boosted its holdings in shares of Gilead Sciences by 39.9% during the fourth quarter. AIMZ Investment Advisors LLC now owns 53,738 shares of the biopharmaceutical company’s stock valued at $3,361,000 after acquiring an additional 15,333 shares during the period. Hedge funds and other institutional investors own 79.94% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Further Reading: Differences Between Momentum Investing and Long Term Investing

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply